ADVIKLA

MPS Pharma Share Price

₹3.69 -0.19 (-4.9%)

04 Mar, 2025 06:34

SIP TrendupStart SIP in ADVIKLA

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume

Investment Returns

  • Over 1 Month -11.72%
  • Over 3 Month -10.65%
  • Over 6 Month -3.91%
  • Over 1 Year + 20.59%
SIP Lightning

Smart Investing Starts Here Start SIP with MPS Pharma for Steady Growth!

Invest Now

MPS Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

MPS Pharma Financials

MPS Pharma Technicals

EMA & SMA

Current Price
₹3.69
-0.19 (-4.9%)
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹3.99
  • 50 Day
  • ₹3.69
  • 100 Day
  • ₹3.15
  • 200 Day
  • ₹2.57

Resistance and Support

3.69 Pivot Speed
  • R3 3.69
  • R2 3.69
  • R1 3.69
  • S1 3.69
  • S2 3.69
  • S3 3.69

What's your outlook on MPS Pharma?

You can only vote for once

MPS Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-12 Quarterly Results
2024-11-14 Quarterly Results
2024-08-13 Quarterly Results
2024-05-30 Audited Results
2024-03-26 Independent Director Meeting

MPS Pharma F&O

MPS Pharma Shareholding Pattern

No data available.

About MPS Pharma

  • NSE Symbol
  • ADVIKLA
  • BSE Symbol
  • 531686
  • ISIN
  • INE537C01019

Similar Stocks to MPS Pharma

MPS Pharma FAQs

MPS Pharma share price is ₹3 As on 04 March, 2025 | 06:20

The Market Cap of MPS Pharma is ₹7.1 Cr As on 04 March, 2025 | 06:20

The P/E ratio of MPS Pharma is -8.2 As on 04 March, 2025 | 06:20

The PB ratio of MPS Pharma is 3.6 As on 04 March, 2025 | 06:20

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23